Most Popular
-
1
NewJeans terminates contract with Ador, embarks on new journey
-
2
Ador claims exclusive contracts with NewJeans still valid
-
3
Heavy, wet snow to fall more often this winter
-
4
SNU professors join growing movement calling for Yoon's resignation
-
5
Presidential office criticizes opposition-led state auditor, prosecutor impeachment motions
-
6
N. Korea launches 32nd wave of trash balloons, anti-S. Korea leaflets
-
7
‘NewJeans are no longer under Ador,’ says legal expert
-
8
NewJeans leave for Japan shows day after unilaterally terminating contract with Ador
-
9
Will Min Hee-jin reunite with NewJeans?
-
10
[From the Scene] At this Starbucks, you need ID: Franchise opens store with view of North Korea
![[From the Scene] At this Starbucks, you need ID: Franchise opens store with view of North Korea](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/29/20241129050068_0.jpg&u=)
![[From the Scene] At this Starbucks, you need ID: Franchise opens store with view of North Korea](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/29/20241129050068_0.jpg&u=)
SK Holdings Co., the holding firm for Korea’s third-largest conglomerate, SK Group, said Friday it plans to spin off its life science business unit in April in a bid to nurture new growth engines.
The new entity, tentatively named SK Biopharm, will be launched on April 1 with a paid-in capital of 20 billion won ($18 million), SK said in a regulatory filing.
Since launching a drug development business in 1993, SK has conducted various research projects and production on drugs for the central nervous system.
The spin-off plan is set to be finalized in a shareholders’ meeting next month, according to SK. (Yonhap News)
The new entity, tentatively named SK Biopharm, will be launched on April 1 with a paid-in capital of 20 billion won ($18 million), SK said in a regulatory filing.
Since launching a drug development business in 1993, SK has conducted various research projects and production on drugs for the central nervous system.
The spin-off plan is set to be finalized in a shareholders’ meeting next month, according to SK. (Yonhap News)
